系统性硬化症中S100A4过表达的临床与致病意义
在94例系统性硬化症(SSc)患者与15例健康对照中,血清S100A4中位浓度在SSc中更高(89.9 ng/mL vs 71.4 ng/mL,p=0.027),且与SSc相关间质性肺病(p=0.025,n=55)及硬皮病肾危象(p=0.026,n=4)相关;SSc皮肤成纤维细胞(SScF)培养上清S100A4高于正常成纤维细胞(NF)(4.19 ng/mL vs 0.28 ng/mL,p<0.0001)。抗S100A4中和单抗AX-202可降低SScF的促纤维化基因与蛋白表达表型,S100A4在NF中诱导的464个差异表达基因在SScF中亦组成性过表达并被AX-202下调。作者认为S100A4在SSc中具有促纤维化作用,血清水平可能作为主要器官表现与疾病严重程度的生物标志物,并支持研究靶向S100A4的治疗潜力。
要点
- SSc患者血清S100A4中位浓度高于健康对照(89.9 vs 71.4 ng/mL,p=0.027)。
- 血清S100A4与SSc相关间质性肺病(p=0.025,n=55)及硬皮病肾危象(p=0.026,n=4)相关。
- AX-202可降低SScF的促纤维化基因与蛋白表达表型,S100A4诱导的NF基因签名与SScF重叠。
核心结论
- 研究结果提供有力证据表明S100A4在SSc中具有促纤维化作用,血清水平可能作为主要器官表现与疾病严重程度的生物标志物。
- 该研究支持检验靶向S100A4在SSc中的治疗潜力。
研究设计与样本
- 采用ELISA测定SSc患者(n=94)与健康对照(n=15)的血清S100A4蛋白浓度。
- 评估弥漫性皮肤型SSc皮肤成纤维细胞(SScF,n=6)与健康对照正常成纤维细胞(NF,n=6)培养中的蛋白表达。
- 在SScF与NF上测试重组S100A4与高亲和力抗S100A4中和单克隆抗体(AX-202)。
- 采用全基因组RNA测序分析S100A4在NF中诱导的基因签名及其与SScF特征性基因表达签名的重叠。
主要发现
- 血清S100A4中位(范围)浓度在SSc中为89.9(15.0-240.0)ng/mL,高于健康对照的71.4(7.9-131.8)ng/mL(p=0.027)。
- 血清S100A4与SSc相关间质性肺病相关(p=0.025,n=55),与硬皮病肾危象相关(p=0.026,n=4)。
- SScF培养上清S100A4中位(范围)浓度为4.19(0.52-8.42)ng/mL,高于NF对照的0.28(0.02-3.29)ng/mL(p<0.0001)。
- AX-202降低SScF的组成性促纤维化基因与蛋白表达表型。
- S100A4在NF中诱导的464个差异表达基因(FDR<0.001且FC>1.5)在SScF中亦组成性过表达并被AX-202下调,这些S100A4依赖基因在SSc中最显著富集的KEGG通路(FDR<0.001)为干细胞多能性调控(4.6倍)与代谢通路(1.9倍)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We have studied the damage-associated molecular pattern protein S100A4 as a driver of fibroblast activation in systemic sclerosis (SSc). METHODS: S100A4 protein concentration was measured by ELISA in serum of SSc (n=94) and healthy controls (n=15). Protein expression in skin fibroblast cultures from diffuse cutaneous SSc (SScF, n=6) and healthy controls (normal fibroblasts (NF), n=6) was assessed. Recombinant S100A4 and a high affinity anti-S100A4 neutralising monoclonal antibody (AX-202) were tested on SScF and NF. RESULTS: Median (range) S100A4 (ng/mL) was higher in serum of SSc (89.9 (15.0-240.0)) than healthy controls (71.4 (7.9-131.8); p=0.027). There was association with SSc-interstitial lung disease (p=0.025, n=55), scleroderma renal crisis (p=0.026, n=4). Median (range) S100A4 (ng/mL) was higher in culture supernatants of SScF (4.19 (0.52-8.42)) than NF controls (0.28 (0.02-3.29); p<0.0001). AX-202 reduced the constitutive profibrotic gene and protein expression phenotype of SScF. Genome-wide RNA sequencing analysis identified an S100A4 activated signature in NF overlapping the hallmark gene expression signature of SScF. Thus, 464 differentially expressed genes (false discovery rate (FDR) <0.001 and fold change (FC) >1.5) induced in NF by S100A4 were also constitutively overexpressed, and downregulated by AX-202, in SScF. Pathway mapping of these S100A4 dependent genes in SSc showed the most significant enriched Kegg pathways (FDR <0.001) were regulation of stem cell pluripotency (4.6-fold) and metabolic pathways (1.9-fold). CONCLUSION: Our findings provide compelling evidence for a profibrotic role for S100A4 in SSc and suggest that serum level may be a biomarker of major organ manifestations and disease severity. This study supports examining the therapeutic potential of targeting S100A4 in SSc.
引用
- Denton CP, Xu S, Zhang F, et al. Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis. Ann Rheum Dis. 2023. PMID: 37414521. doi:10.1136/ard-2023-223862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。